Financial Performance - The company's revenue for Q1 2024 was ¥138,059,120.72, a decrease of 28.57% compared to ¥193,286,953.47 in the same period last year[5] - Net profit attributable to shareholders was ¥37,381,597.20, down 6.37% from ¥39,922,932.84 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 138,059,120.72, a decrease of 28.6% compared to CNY 193,286,953.47 in the same period last year[20] - Net profit for Q1 2024 was CNY 37,381,597.20, a decline of 6.4% from CNY 39,922,932.84 in Q1 2023[21] - The basic and diluted earnings per share for Q1 2024 were both CNY 0.13, compared to CNY 0.14 in Q1 2023[21] Cash Flow and Operating Activities - The net cash flow from operating activities improved significantly to ¥14,331,076.29, compared to a negative cash flow of ¥15,751,558.42 in the previous year, marking a 190.98% increase[5] - Operating cash flow for the period was CNY 14,331,076.29, a significant improvement from a negative cash flow of CNY -15,751,558.42 in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,542,264,263.63, a slight decrease of 0.17% from ¥2,546,570,975.79 at the end of the previous year[5] - Total current assets decreased from CNY 2,098,949,170.23 at the beginning of the period to CNY 2,062,714,828.89 at the end of the period, a reduction of approximately 1.73%[16] - Cash and cash equivalents decreased from CNY 1,694,326,514.68 to CNY 1,663,102,024.22, a decline of about 1.84%[16] - Accounts receivable increased from CNY 52,444,817.42 to CNY 70,319,422.17, representing a growth of approximately 34.06%[16] - Inventory decreased from CNY 173,804,685.14 to CNY 167,614,148.30, a decrease of about 3.43%[16] - Total liabilities decreased from CNY 189,886,134.37 to CNY 147,328,381.49, a reduction of approximately 22.49%[17] - Non-current assets increased from CNY 447,621,805.56 to CNY 479,549,434.74, an increase of about 7.13%[17] - The total equity remained stable at CNY 2,394,935,882.14, with no significant changes reported[17] Research and Development - Research and development expenses increased by 53.73% to ¥10,942,220.83, driven by higher investment in new product development[9] - Research and development expenses increased to CNY 10,942,220.83, up 54.5% from CNY 7,117,899.04 in the same quarter last year[20] Financial Income and Expenses - The company reported a significant increase in financial income, with financial expenses showing a decrease of 52.82% due to increased interest income[9] - The company recorded a financial income of CNY 17,106,058.00, compared to CNY 12,295,014.61 in the previous year, reflecting a growth of 39.3%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,681, with no preferred shareholders[12] - The company reported a total equity attributable to shareholders of CNY 2,394,935,882.14, an increase from CNY 2,356,684,841.42 year-over-year[18] Other Information - The first quarter report has not been audited[25] - The new accounting standards will be implemented starting in 2024[25] - The board of directors meeting was held on April 26, 2024[26]
亨迪药业(301211) - 2024 Q1 - 季度财报